Ventriculography Modality in Detection and Evaluation of Cardiotoxicity in Breast Cancer Patients Receiving Chemotherapy: A Literature Review

Tatyana Milenia, Budi Darmawan, Erwin Affandi Soeriadi Koesomah


Background: Ventriculography or Multigated Acquisition Scanning (MUGA) has been the gold standard for baseline and serial assessment of Left Ventricular Ejection Fraction (LVEF) for cardiotoxicity since 1970. However, several modalities have been proposed to substitute Ventriculography. This study aimed to find out whether Ventriculography can still be considered the gold standard to monitor and detect cardiotoxicity before, during, and after administration of the chemotherapy and compare Ventriculography with Cardiac Magnetic Resonance (CMR) and Echocardiography (Echo).

Methods: A literature review was done by searching original literature with keyword combinations on PubMed, Cochrane, and ClinicalKey in the past five years (2016–2021) with language restrictions only in English. Of 1,381 pieces of literature, five pieces are included to review in this study. Results: Ventriculography has high sensitivity and specificity in monitoring and detecting cardiotoxicity. Other modalities are CMR and Echo. CMR is more accurate although it is costly whilst Echo has high interobserver variability. Ventriculography and CMR have not shown interchangeable results. The literature also shows that Ventriculography could evaluate cardiotoxicity by assessing diastolic function.

Conclusions: Ventriculography can still be used as the gold standard for monitoring cardiac function and detecting cardiotoxicity at an affordable price and with acceptable side effects. It recommends choosing only one modality for serial monitoring due to not interchangeable results among modalities


breast cancer, cardiotoxicity, chemotherapy, CMR, Echo, MUGA, ventriculography


World Health Organization. Age standardized (World) incidence rates, breast, all ages [Internet]. International Agency for Research on Cancer; 2021 [cited 2021 Sep 3]. Available from:

World Health Organization. Cancer Fact Sheets: Breast Cancer [Internet]. Lyon: International Agency for Research on Cancer; 2021 [cited 2021 Sep 3]. Available from:

World Health Organization. Indonesia Fact Sheet [Internet]. Lyon: International Agency for Research on Cancer; 2021 [cited 2021 Sep 3]. Available from:

Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 1;20(3):719–26.

Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and Trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006 Apr 20;24(12):1831–8.

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809–20.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005 Oct 20;353(16):1659–72.

Yu AF, Flynn JR, Moskowitz CS, et al. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer. JAMA Cardiol. 2020 Mar 1;5(3):309-317.

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673–84.

Barac A, Murtagh G, Carver JR, et al. Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol. 2015 Jun 30;65(25):2739–46.

Shenoy C, Klem I, Crowley AL, et al. Cardiovascular Complications of Breast Cancer Therapy in Older Adults. Oncologist. 2011 Aug;16(8):1138.

Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1659–72.

Goldhar HA, Yan AT, Ko DT, et al. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. J Natl Cancer Inst. 2015 Jan 1;108(1).

Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004 Jan 15;22(2):322-9.

Slamon D, Eiermann W, Robert N, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. 2011 Oct 5;365(14):1273–83.

Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002 Mar 1;20(5):1215–21.

Honda K, Takeshita K, Murotani K, et al. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer. Breast Cancer. 2017;24(2):312–8.

Song L, Brezden-Masley C, Ramanan V, et al. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab. Am J Cardiol. 2019;123(7):1173–9.

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.

Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979 Feb 8;300(6):278–83.

Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080–91.

Bodar V, Modi K. Radionuclide Ventriculography [Internet]. StatPearls. StatPearls Publishing; 2020 [cited 2021 Jan 14]. Available from:

Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94(4 I):430–5.

Shureiqi I, Cantor SB, Lippman SM, et al. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer. 2002;86:226–32.

Lazor L, Russell JC, DaSilva J, Radford M. Use of the multiple uptake gated acquisition scan for the preoperative assessment of cardiac risk. Surg Gynecol Obstet. 1988 Sep;167(3):234–8.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768–801.

Valbuena-López S, Hinojar R, Puntmann VO. Cardiovascular Magnetic Resonance in Cardiology Practice: A Concise Guide to Image Acquisition and Clinical Interpretation. Rev Española Cardiol (English Ed). 2016;69(2):202–10.

Kinno M, Nagpal P, Horgan S, Waller AH. Comparison of Echocardiography, Cardiac Magnetic Resonance, and Computed Tomographic Imaging for the Evaluation of Left Ventricular Myocardial Function: Part 1 (Global Assessment). Curr Cardiol Rep. 2017 Jan;19(1):9.

Tak T, Jaekel CM, Gharacholou SM, et al. Measurement of Ejection Fraction by Cardiac Magnetic Resonance Imaging and Echocardiography to Monitor Doxorubicin-Induced Cardiotoxicity. Int J Angiol. 2020;29(1):45–51.

Dhir V, Yan AT, Nisenbaum R, et al. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving Trastuzumab: a prospective observational study. Int J Cardiovasc Imaging. 2019;35(11):2085–93.

Reuvekamp EJ, Bulten BF, Nieuwenhuis AA, et al. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). J Nucl Cardiol. 2016;23(4):824–32.

Yang SN, Sun SS, Zhang G, et al. Left ventricular ejection fraction estimation using mutual information on technetium-99m multiple-gated SPECT scans. BioMedical Engineering OnLine. 2015 Dec 23;14(1):1–10.

Huang H, Nijjar PS, Misialek JR, et al. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: Comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2017;19(1):1–9.

Klein R, Nadouri D, Osler E, et al. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. Nucl Med Commun. 2019;40(1):22–9.

Mirea O, Pagourelias ED, Duchenne J, et al. Intervendor Differences in the Accuracy of Detecting Regional Functional Abnormalities: A Report From the EACVI-ASE Strain Standardization Task Force. JACC Cardiovasc Imaging. 2018 Jan 1;11(1):25–34.

Mirea O, Pagourelias ED, Duchenne J, et al. Variability and Reproducibility of Segmental Longitudinal Strain Measurement: A Report From the EACVI-ASE Strain Standardization Task Force. JACC Cardiovasc Imaging. 2018 Jan 1;11(1):15–24.

Nabeshima Y, Seo Y, Takeuchi M. A review of current trends in three-dimensional analysis of left ventricular myocardial strain. Cardiovasc Ultrasound. 2020;18(1):1–21.

Purkayastha K, Seth R, Seth S, Lyon A. Cancer therapy-induced cardiotoxicity: Review and algorithmic approach toward evaluation. J Pract Cardiovasc Sci. 2017;3(2):82.

D'Amore C, Gargiulo P, Paolillo S, et al. Nuclear imaging in detection and monitoring of cardiotoxicity. World J Radiol. 2014 Jul 28;6(7):486-92.

Odak M, Kayani WT. MUGA Scan [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2022 Jan 30]. Available from:

Chen J, Einstein AJ, Fazel R, et al. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. J Am Coll Cardiol. 2010;56(9):702-11.

Harake D, Franco VI, Henkel JM, et al. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012 Jul;8(4):647-70.

Full Text: PDF

DOI: 10.33371/ijoc.v16i3.897

Article Metrics

Abstract view : 86 times
PDF - 43 times


  • There are currently no refbacks.

Copyright (c) 2022 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.